Last reviewed 2026-04-23 · How we verify

Vandetanib (SAR390530)

Vandetanib is a tyrosine kinase inhibitor that targets RET, VEGFR2, and EGFR.

Vandetanib is a tyrosine kinase inhibitor that targets RET, VEGFR2, and EGFR. Used for Medullary thyroid cancer.

At a glance

Mechanism of action

It works by inhibiting the activity of these kinases, which are involved in the growth and spread of cancer cells. This leads to a decrease in tumor growth and angiogenesis.

Approved indications

• Medullary thyroid cancer

Common side effects

• Diarrhea
• Nausea
• Fatigue
• Hypertension
• Rash

Key clinical trials

• To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer (PHASE4)
• An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer (PHASE3)
• Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment (PHASE3)
• Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients (PHASE3)
• Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer (PHASE3)
• Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer (PHASE2)
• Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer (PHASE2)
• A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.